Judge approves $120m Momenta and Sandoz settlement

A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Amphastar enters into $59m settlement with Sandoz and Momenta

20 June 2019 US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.

Big Pharma

Sandoz and Momenta to pay $120m to end antitrust suit

24 December 2019 Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.

Generics

Ex-Sandoz exec pleads guilty to price fixing in generics probe

18 February 2020 Hector Armando Kellum, a former senior executive at Novartis division Sandoz, has pleaded guilty to his role in a conspiracy to fix prices for generic drugs, the US Department of Justice announced.

More on this story

Big Pharma

Amphastar enters into $59m settlement with Sandoz and Momenta

20 June 2019 US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.

Big Pharma

Sandoz and Momenta to pay $120m to end antitrust suit

24 December 2019 Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.

Generics

Ex-Sandoz exec pleads guilty to price fixing in generics probe

More on this story

Big Pharma

Amphastar enters into $59m settlement with Sandoz and Momenta

20 June 2019 US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.

Big Pharma

Sandoz and Momenta to pay $120m to end antitrust suit

24 December 2019 Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.

Generics

Ex-Sandoz exec pleads guilty to price fixing in generics probe